A-Cube
Notice of Exhibition at JACLaS EXPO 2025
Exhibition Information ProteoBridge Inc. will be e…
NEWS Index
NEWS
ProteoBridge Inc. Raises 40 Million JPY in Third-Party Allocation with JMTC Capital LLC
ProteoBridge Inc. has raised 40 million JPY throug…
A-Cube
Announcement of Exhibition at the 33rd Annual Meeting of the Japan Sjögren’s Syndrome Society (Ongoing)
The 33rd Annual Meeting of the Japan Sjögren’s Syn…
NEWS
ProteoBridge Announces Third-Party Allotment to Strengthen Research Testing Services and Advance New Product Development
ProteoBridge Inc. is pleased to announce that it h…
A-Cube
34th A-Cube® Research Test Seminar Announcement
The 34th A-Cube® Research Test Seminar will be hel…
NEWS
ProteoBridge Inc. Representative Appointed as Director of the Japan Bioinformatics Consortium (JBIC)
ProteoBridge Inc. (Head Office: Koto-ku, Tokyo) is…
A-Cube
Our Technology Featured in Allergy & Rheumatic Diseases September 2025 Issue – Special Feature on “Allergen Immunotherapy”
In the September 2025 issue of Allergy & Rheum…
A-Cube
🎉 The 11th Annual Meeting of the Japanese Society of Myology Has Officially Begun!
At our booth, we are showcasing a wide range of se…
HuPEX
HuPEX®-Powered Proteomics Research Published in Journal of Proteome Research
Tokyo, Japan – July 25, 2025 – ProteoBridge Inc. (…
Conferences and Exhibitions
Proteo-Bridge Inc. Exhibiting at the Corporate Booth of the “2025 Japan Health JETRO Pavilion”
Proteo-Bridge Inc. is pleased to announce our part…